3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Solid Tumor
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Mesothelioma, Malignant
1
Mesothelioma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Thiotepa
3
Filgrastim
3
sargramostim
2
pembrolizumab
2
belinostat
2
Melphalan
2
Granulocyte Colony-Stimulating Factor
2
Cyclophosphamide
2
Busulfan
2
tocilizumab
1
spartalizumab
1
atezolizumab
1
Topotecan
1
Stem Cell Transplantation
1
Sirolimus
1
Radiotherapy, Intensity-Modulated
1
Quality of Life
1
Plicamycin
1
Peripheral Blood Stem Cell Transplantation
1
Patient Reported Outcome Measures
1
Nivolumab
1
Molecular Diagnostic Techniques
1
Mesna
1
Ipilimumab
1
Interferon-gamma
1
Interferon-alpha
1
Immunotherapy
1
Ifosfamide
1
Fluorouracil
1
FANG vaccine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Kidney Neoplasms
×
Blood Component Removal
×
Other solid neoplasm
×
Clear all
NCT04981119
2026-06-02
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
200 enrolled